Anlotinib combined with chemotherapy in metastatic desmoplastic small round cell tumor: a case report
Abstract
BackgroundDesmoplastic small round cell tumor (DSRCT), a rare and highly aggressive sarcoma with predilection for adolescents, diagnosed through histopathology, immunohistochemistry, and cytogenetic studies to confirm its variable phenotypic expression and characteristic chromosomal translocation. Anlotinib is an orally administered multi-target tyrosine kinase inhibitor with anti-angiogenic and anti-proliferative properties. This case report describes a sustained objective response to chemotherapy combined with anlotinib in a young man with DSRCT, suggesting potential clinical activity for this aggressive sarcoma subtype.Case descriptionA 23-year-old male presented with a 3-month history of a progressively enlarging right lower abdominal mass accompanied by localized tenderness. Diagnostic workup revealed multifocal peritoneal masses with retroperitoneal and thoracic lymphadenopathy on imaging. 18F-FDG PET/CT revealed hypermetabolic lesions involving the ileocecal junction, retroperitoneal lymph nodes, thoracic vertebrae, and pleura, confirming extensive multiorgan metastases involving the peritoneum, retroperitoneal and thoracic lymph nodes, pleura, and thoracolumbar vertebrae. Histopathology demonstrated classic small round cells within desmoplastic stroma, with immunohistochemical co-expression of epithelial (CK/EMA), mesenchymal (vimentin), and myogenic markers (paranuclear desmin+). Molecular confirmation of the EWSR1-WT1 fusion via Next-generation sequencing (NGS) established definitive diagnosis. Treatment involved a multidisciplinary strategy combining systemic therapy with VEC/IE (vincristine/epirubicin/cyclophosphamide alternating with ifosfamide/etoposide) chemotherapy and anlotinib. Ultimately, the patient had completed 8 cycles of chemotherapy combined with anlotinib, followed by anlotinib maintenance therapy, achieving a progression-free survival (PFS) of 17 months.ConclusionThis case suggests potential clinical activity of anlotinib-based multimodal therapy in metastatic DSRCT and advocates the integration of immunohistochemistry with molecular detection of EWSR1-WT1 fusion for diagnostic precision, guiding biologically rational treatment paradigms.
Related
- Radiotherapy combined with anlotinib for recurrent high-grade soft tissue sarcoma of the scalp: a case report
- Cytoreductive cystectomy combined with chemotherapy versus chemotherapy alone in the treatment of metastatic bladder cancer: A retrospective comparative study.
- Case Report: Apparent progressive complete mismatch repair protein loss during platinum-based chemotherapy in metastatic rectal neuroendocrine tumour grade 2
- Case Report: Bilateral optic disc edema with papillophlebitis-like features following combined cisplatin and capecitabine chemotherapy
- PF chemotherapy combined with a PD-1/CTLA-4 bispecific antibody as first-line treatment in patients with recurrent/metastatic head and neck squamous cell carcinoma: a prospective, single-arm, phase II clinical study
BibTeX
@article{dong2026anlotinib,
title = {{Anlotinib combined with chemotherapy in metastatic desmoplastic small round cell tumor: a case report}},
author = {Yalu Dong and Weiwei He and Qian Xie and Liping Yang and Yongqiang Wang and XiaoWei Zhao and Zheng Li},
journal = {Frontiers in Oncology},
year = {2026},
month = nov,
doi = {10.3389/fonc.2026.1990056},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1990056},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Anlotinib combined with chemotherapy in metastatic desmoplastic small round cell tumor: a case report
AU - Yalu Dong
AU - Weiwei He
AU - Qian Xie
AU - Liping Yang
AU - Yongqiang Wang
AU - XiaoWei Zhao
AU - Zheng Li
PY - 2026
DA - 2026/11/06
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1990056
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1990056
AB - BackgroundDesmoplastic small round cell tumor (DSRCT), a rare and highly aggressive sarcoma with predilection for adolescents, diagnosed through histopathology, immunohistochemistry, and cytogenetic studies to confirm its variable phenotypic expression and characteristic chromosomal translocation. Anlotinib is an orally administered multi-target tyrosine kinase inhibitor with anti-angiogenic and anti-proliferative properties. This case report describes a sustained objective response to chemotherapy combined with anlotinib in a young man with DSRCT, suggesting potential clinical activity for this aggressive sarcoma subtype.Case descriptionA 23-year-old male presented with a 3-month history of a progressively enlarging right lower abdominal mass accompanied by localized tenderness. Diagnostic workup revealed multifocal peritoneal masses with retroperitoneal and thoracic lymphadenopathy on imaging. 18F-FDG PET/CT revealed hypermetabolic lesions involving the ileocecal junction, retroperitoneal lymph nodes, thoracic vertebrae, and pleura, confirming extensive multiorgan metastases involving the peritoneum, retroperitoneal and thoracic lymph nodes, pleura, and thoracolumbar vertebrae. Histopathology demonstrated classic small round cells within desmoplastic stroma, with immunohistochemical co-expression of epithelial (CK/EMA), mesenchymal (vimentin), and myogenic markers (paranuclear desmin+). Molecular confirmation of the EWSR1-WT1 fusion via Next-generation sequencing (NGS) established definitive diagnosis. Treatment involved a multidisciplinary strategy combining systemic therapy with VEC/IE (vincristine/epirubicin/cyclophosphamide alternating with ifosfamide/etoposide) chemotherapy and anlotinib. Ultimately, the patient had completed 8 cycles of chemotherapy combined with anlotinib, followed by anlotinib maintenance therapy, achieving a progression-free survival (PFS) of 17 months.ConclusionThis case suggests potential clinical activity of anlotinib-based multimodal therapy in metastatic DSRCT and advocates the integration of immunohistochemistry with molecular detection of EWSR1-WT1 fusion for diagnostic precision, guiding biologically rational treatment paradigms.
SN - 2234-943X
ER -